Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Baxter
Moodys
Mallinckrodt
Boehringer Ingelheim

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR LESCOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lescol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00421005 ↗ Fluvastatin After Heart Transplantation Unknown status University of Bologna Phase 4 2004-11-01 Statin therapy is a treatment with a proven positive impact on survival after heart transplantation. However, it is unclear whether the beneficial effect of this class of drugs depends solely on their LDL-lowering properties or on anti-inflammatory and immuno-modulatory properties. Thus, this study was designed to compare safety and efficacy of two different strategies: 1. high fixed statin dose vs. 2. low starting dose with LDL-driven doses adjustments.
NCT00487318 ↗ Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin Completed US Department of Veterans Affairs Phase 2 2007-06-01 Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
NCT00487318 ↗ Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin Completed VA Office of Research and Development Phase 2 2007-06-01 Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
NCT00487318 ↗ Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin Completed Bader, Ted, M.D. Phase 2 2007-06-01 Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.
NCT00532311 ↗ Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia Terminated Takeda Phase 3 2007-07-01 The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with statins on cholesterol levels in subjects with hypercholesterolemia
NCT00814723 ↗ Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk Completed Medical University of Graz Phase 4 2005-09-01 Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients with primary hypercholesterolemia where the combination therapy with statins (HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total cholesterol levels compared to monotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lescol

Condition Name

Condition Name for Lescol
Intervention Trials
Hypercholesterolemia 3
Atherosclerosis 1
Prostate Cancer 1
Chronic Hepatitis C 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lescol
Intervention Trials
Hypercholesterolemia 3
Coronary Disease 2
Coronary Artery Disease 2
Myocardial Ischemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lescol

Trials by Country

Trials by Country for Lescol
Location Trials
United States 37
China 2
Switzerland 2
Canada 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lescol
Location Trials
California 2
Massachusetts 2
Oklahoma 2
Oregon 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lescol

Clinical Trial Phase

Clinical Trial Phase for Lescol
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lescol
Clinical Trial Phase Trials
Completed 7
Unknown status 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lescol

Sponsor Name

Sponsor Name for Lescol
Sponsor Trials
Novartis 2
Peking University First Hospital 1
Beijing Anzhen Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lescol
Sponsor Trials
Other 10
Industry 4
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Mallinckrodt
Baxter
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.